Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia

被引：6
|
作者：
Tam, Constantine S. [1 ,8 ]
Trotman, Judith [2 ,3 ]
Opat, Stephen [4 ,5 ]
Stern, Jennifer C. [6 ]
Allewelt, Heather [6 ]
By, Kunthel [6 ]
Novotny, William [6 ]
Huang, Jane [6 ]
Tedeschi, Alessandra [7 ]
机构：
[1] Monash Univ, Alfred Hosp, Melbourne, Vic, Australia
[2] Concord Repatriat Gen Hosp, Concord, NSW, Australia
[3] Univ Sydney, Concord, NSW, Australia
[4] Monash Hlth, Clayton, Vic, Australia
[5] Monash Univ, Clayton, Vic, Australia
[6] BeiGene, San Mateo, CA USA
[7] ASST Grande Osped Metropolitano Niguarda, Milan, Italy
[8] Alfred Hosp, 55 Commercial Rd, Melbourne, Vic, Australia
来源：
BLOOD ADVANCES | 2023年 / 7卷 / 12期
关键词：
D O I：
10.1182/bloodadvances.2022008990
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2884 / 2887
页数：4
相关论文
共 50 条
  • [41] Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations
    Nobre, Carmen F.
    Newman, Matthew J.
    DeLisa, Anne
    Newman, Pauline
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (02) : 255 - 263
  • [42] Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations
    Carmen F. Nobre
    Matthew J. Newman
    Anne DeLisa
    Pauline Newman
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 255 - 263
  • [43] MRD-negative complete remission in relapsed refractory hairy cell leukemia with bendamustine and obinutuzumab
    Sadeghi, Navid
    Li, Hsiao C.
    ANNALS OF HEMATOLOGY, 2018, 97 (04) : 723 - 724
  • [44] Vemurafenib for relapsed or refractory hairy-cell leukaemia
    Baker, Holly
    LANCET ONCOLOGY, 2015, 16 (13): : E484 - E484
  • [45] MRD-negative complete remission in relapsed refractory hairy cell leukemia with bendamustine and obinutuzumab
    Navid Sadeghi
    Hsiao C. Li
    Annals of Hematology, 2018, 97 : 723 - 724
  • [46] Changes in immune cell numbers and profile during long-term zanubrutinib treatment in treatment-naive and relapsed/refractory patients with chronic lymphocytic leukemia
    Andersson, Maria
    Mulder, Tom
    Heimersson, Kia
    Sonnert-Husa, Sonja
    Giertz, Annika
    Karlsson, Claes
    Lundin, Jeanette
    Hansson, Lotta
    Osterborg, Anders
    Palma, Marzia
    LEUKEMIA & LYMPHOMA, 2023, 64 : S23 - S24
  • [47] Refractory hairy cell leukemia-variant
    Hu, Zhihong
    Sun, Yi
    Wang, Wei
    Medeiros, L. Jeffrey
    Kanagal-Shamanna, Rashmi
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (12) : 1398 - 1399
  • [48] Novel therapeutic options for relapsed hairy cell leukemia
    Jain, Preetesh
    Polliack, Aaron
    Ravandi, Farhad
    LEUKEMIA & LYMPHOMA, 2015, 56 (08) : 2264 - 2272
  • [49] Treatment of hairy cell leukemia
    Chihara, Dai
    Kreitman, Robert J.
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (10) : 1107 - 1117
  • [50] Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy
    Handa, Shivani
    Lee, Jeong-Ok
    Derkach, Andriy
    Stone, Richard M.
    Saven, Alan
    Altman, Jessica K.
    Grever, Michael R.
    Rai, Kanti R.
    Shukla, Madhulika
    Vemuri, Shreya
    Montoya, Skye
    Taylor, Justin
    Abdel-Wahab, Omar
    Tallman, Martin S.
    Park, Jae H.
    BLOOD, 2022, 140 (25) : 2663 - 2671
12345